;PMID: 9882527
;source_file_2931.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..41] = [t:0..41]
;1)sentence:[e:47..159] = [t:47..159]
;2)section:[e:163..233] = [t:163..233]
;3)section:[e:237..383] = [t:237..383]
;4)sentence:[e:387..594] = [t:387..594]
;5)sentence:[e:595..775] = [t:595..775]
;6)sentence:[e:776..1028] = [t:776..1028]
;7)sentence:[e:1029..1148] = [t:1029..1148]
;8)sentence:[e:1149..1311] = [t:1149..1311]
;9)sentence:[e:1312..1403] = [t:1312..1403]
;10)section:[e:1404..1435] = [t:1404..1435]
;11)section:[e:1439..1483] = [t:1439..1483]

;section 0 Span:0..41
;Exp Cell Res.  1999 Jan 10;246(1):183-92.
(SEC
  (FRAG (NNP:[0..3] Exp) (NNP:[4..8] Cell) (NNP:[9..12] Res) (.:[12..13] .)
        (CD:[15..19] 1999) (NNP:[20..23] Jan) (CD:[24..26] 10)
        (CD:[26..30] ;246) (-LRB-:[30..31] -LRB-) (CD:[31..32] 1)
        (-RRB-:[32..33] -RRB-) (::[33..34] :) (CD:[34..37] 183) (::[37..38] -)
        (CD:[38..40] 92) (.:[40..41] .)))

;sentence 1 Span:47..159
;Depletion of glutathione by buthionine sulfoxine is cytotoxic for human 
;neuroblastoma cell lines via apoptosis.
;[120..133]:malignancy-type:"neuroblastoma"
(SENT
  (S-HLN
    (NP-SBJ
      (NP (NN:[47..56] Depletion))
      (PP (IN:[57..59] of)
        (NP (NN:[60..71] glutathione)))
      (PP (IN:[72..74] by)
        (NP (NN:[75..85] buthionine) (NN:[86..95] sulfoxine))))
    (VP (VBZ:[96..98] is)
      (ADJP-PRD (JJ:[99..108] cytotoxic))
      (PP (IN:[109..112] for)
        (NP (JJ:[113..118] human) (NN:[120..133] neuroblastoma)
            (NN:[134..138] cell) (NNS:[139..144] lines)))
      (PP (IN:[145..148] via)
        (NP (NN:[149..158] apoptosis))))
    (.:[158..159] .)))

;section 2 Span:163..233
;Anderson CP, Tsai JM, Meek WE, Liu RM, Tang Y, Forman HJ, Reynolds CP.
(SEC
  (FRAG (NNP:[163..171] Anderson) (NN:[172..174] CP) (,:[174..175] ,)
        (NNP:[176..180] Tsai) (NNP:[181..183] JM) (,:[183..184] ,)
        (NNP:[185..189] Meek) (NNP:[190..192] WE) (,:[192..193] ,)
        (NNP:[194..197] Liu) (NNP:[198..200] RM) (,:[200..201] ,)
        (NNP:[202..206] Tang) (NNP:[207..208] Y) (,:[208..209] ,)
        (NNP:[210..216] Forman) (NNP:[217..219] HJ) (,:[219..220] ,)
        (NNP:[221..229] Reynolds) (NN:[230..232] CP) (.:[232..233] .)))

;section 3 Span:237..383
;Division of Hematology-Oncology, Childrens Hospital Los Angeles, 4650 Sunset 
;Boulevard, Los Angeles, California, 90027, USA. cpreynol@hsc.usc.edu
(SEC
  (FRAG (NNP:[237..245] Division) (IN:[246..248] of)
        (NNP:[249..268] Hematology-Oncology) (,:[268..269] ,)
        (NNP:[270..279] Childrens) (NNP:[280..288] Hospital)
        (NNP:[289..292] Los) (NNP:[293..300] Angeles) (,:[300..301] ,)
        (CD:[302..306] 4650) (NNP:[307..313] Sunset) (NNP:[315..324] Boulevard)
        (,:[324..325] ,) (NNP:[326..329] Los) (NNP:[330..337] Angeles)
        (,:[337..338] ,) (NNP:[339..349] California) (,:[349..350] ,)
        (CD:[351..356] 90027) (,:[356..357] ,) (NNP:[358..361] USA)
        (.:[361..362] .) ('':[363..383] cpreynol@hsc.usc.edu)))

;sentence 4 Span:387..594
;Buthionine sulfoximine (BSO) selectively inhibits glutathione (GSH) synthesis
; and has been used to sensitize tumor cells to alkylating agents, but has
;minimal  single-agent cytotoxicity for most cell types.
(SENT
  (S
    (NP-SBJ-1
      (NP (NN:[387..397] Buthionine) (NN:[398..409] sulfoximine))
      (NP (-LRB-:[410..411] -LRB-) (NN:[411..414] BSO) (-RRB-:[414..415] -RRB-)))
    (ADVP (RB:[416..427] selectively))
    (VP
      (VP
        (VP (VBZ:[428..436] inhibits)
          (NP
            (NML
              (NML (NN:[437..448] glutathione))
              (NML (-LRB-:[449..450] -LRB-) (NN:[450..453] GSH)
                   (-RRB-:[453..454] -RRB-)))
            (NN:[455..464] synthesis)))
        (CC:[466..469] and)
        (VP (VBZ:[470..473] has)
          (VP (VBN:[474..478] been)
            (VP (VBN:[479..483] used)
              (NP-1 (-NONE-:[483..483] *))
              (S-PRP
                (NP-SBJ (-NONE-:[483..483] *))
                (VP (TO:[484..486] to)
                  (VP (VB:[487..496] sensitize)
                    (NP (NN:[497..502] tumor) (NNS:[503..508] cells))
                    (PP (TO:[509..511] to)
                      (NP (VBG:[512..522] alkylating) (NNS:[523..529] agents))))))))))
      (,:[529..530] ,) (CC:[531..534] but)
      (VP (VBZ:[535..538] has)
        (NP (JJ:[539..546] minimal)
          (NML (JJ:[548..554] single) (HYPH:[554..555] -) (NN:[555..560] agent))
          (NN:[561..573] cytotoxicity))
        (PP (IN:[574..577] for)
          (NP (JJS:[578..582] most) (NN:[583..587] cell) (NNS:[588..593] types)))))
    (.:[593..594] .)))

;sentence 5 Span:595..775
;We determined the cytotoxicity of  BSO for 18 (12 MYCN amplified; 6 MYCN
;nonamplified) human neuroblastoma cell  lines using DIMSCAN, a digital image
;microscopy cytotoxicity assay.
;[645..649]:gene-rna:"MYCN"
;[650..659]:variation-type:"amplified"
;[663..667]:gene-rna:"MYCN"
;[688..701]:malignancy-type:"neuroblastoma"
(SENT
  (S
    (NP-SBJ (PRP:[595..597] We))
    (VP (VBD:[598..608] determined)
      (NP
        (NP (DT:[609..612] the) (NN:[613..625] cytotoxicity))
        (PP (IN:[626..628] of)
          (NP (NN:[630..633] BSO))))
      (PP (IN:[634..637] for)
        (NP (CD:[638..640] 18)
          (PRN (-LRB-:[641..642] -LRB-)
            (NP
              (NP (CD:[642..644] 12)
                (ADJP (NN:[645..649] MYCN) (VBN:[650..659] amplified)))
              (::[659..660] ;)
              (NP
                (NP (CD:[661..662] 6) (NN:[663..667] MYCN))
                (ADJP (JJ:[668..680] nonamplified))))
            (-RRB-:[680..681] -RRB-))
          (JJ:[682..687] human) (NN:[688..701] neuroblastoma)
           (NN:[702..706] cell) (NNS:[708..713] lines)))
      (S-MNR
        (NP-SBJ (-NONE-:[713..713] *))
        (VP (VBG:[714..719] using)
          (NP
            (NP (NN:[720..727] DIMSCAN))
            (,:[727..728] ,)
            (NP (DT:[729..730] a) (JJ:[731..738] digital) (NN:[739..744] image)
                (NN:[745..755] microscopy) (NN:[756..768] cytotoxicity)
                (NN:[769..774] assay))))))
    (.:[774..775] .)))

;sentence 6 Span:776..1028
;D-L(R:S) BSO  was highly cytotoxic (>3 logs of cell kill) for most
;neuroblastoma cell lines,  with 17/18 cell lines having IC90 values (range 2.
;1->1000 microM) below  equivalent steady state plasma levels of L(R:S) BSO
;reported in adult human  trials.
;[843..856]:malignancy-type:"neuroblastoma"
(SENT
  (S
    (NP-SBJ (NN:[776..784] D-L-LRB-R:S-RRB-) (NN:[785..788] BSO))
    (VP (VBD:[790..793] was)
      (ADJP-PRD (RB:[794..800] highly) (JJ:[801..810] cytotoxic)
        (PRN (-LRB-:[811..812] -LRB-)
          (NP
            (QP (SYM:[812..813] >) (CD:[813..814] 3))
            (NNS:[815..819] logs))
          (PP (IN:[820..822] of)
            (NP (NN:[823..827] cell) (NN:[828..832] kill)))
          (-RRB-:[832..833] -RRB-)))
      (PP (IN:[834..837] for)
        (NP (JJS:[838..842] most) (NN:[843..856] neuroblastoma)
            (NN:[857..861] cell) (NNS:[862..867] lines)))
      (,:[867..868] ,)
      (PP (IN:[870..874] with)
        (NP
          (NP
            (NP (CD:[875..877] 17))
            (PP (SYM:[877..878] /)
              (NP (CD:[878..880] 18) (NN:[881..885] cell) (NNS:[886..891] lines))))
          (VP (VBG:[892..898] having)
            (NP
              (NP (NN:[899..903] IC90) (NNS:[904..910] values)
                (PRN (-LRB-:[911..912] -LRB-)
                  (S
                    (NP-SBJ (NN:[912..917] range) (CD:[918..920] 2.))
                    (NP-PRD
                      (QP (CD:[921..922] 1) (SYM:[922..924] ->)
                          (CD:[924..928] 1000))
                      (NN:[929..935] microM)))
                  (-RRB-:[935..936] -RRB-)))
              (PP (IN:[937..942] below)
                (NP
                  (NP
                    (NP (JJ:[944..954] equivalent)
                      (NML (JJ:[955..961] steady) (NN:[962..967] state))
                      (NN:[968..974] plasma) (NNS:[975..981] levels))
                    (PP (IN:[982..984] of)
                      (NP (NN:[985..991] L-LRB-R:S-RRB-) (NN:[992..995] BSO))))
                  (VP (VBN:[996..1004] reported)
                    (NP (-NONE-:[1004..1004] *))
                    (PP (IN:[1005..1007] in)
                      (NP (JJ:[1008..1013] adult) (JJ:[1014..1019] human)
                          (NNS:[1021..1027] trials)))))))))))
    (.:[1027..1028] .)))

;sentence 7 Span:1029..1148
;Cell lines with genomic amplification of MYCN were more sensitive to BSO 
;than MYCN nonamplified cell lines (P = 0.04).
;[1053..1066]:variation-type:"amplification"
;[1070..1074]:gene-rna:"MYCN"
;[1108..1112]:gene-rna:"MYCN"
(SENT
  (S
    (NP-SBJ
      (NP (NN:[1029..1033] Cell) (NNS:[1034..1039] lines))
      (PP (IN:[1040..1044] with)
        (NP
          (NP (JJ:[1045..1052] genomic) (NN:[1053..1066] amplification))
          (PP (IN:[1067..1069] of)
            (NP (NN:[1070..1074] MYCN))))))
    (VP (VBD:[1075..1079] were)
      (ADJP-PRD
        (ADJP (RBR:[1080..1084] more) (JJ:[1085..1094] sensitive)
          (PP (TO:[1095..1097] to)
            (NP (NN:[1098..1101] BSO))))
        (PP (IN:[1103..1107] than)
          (NP
            (ADJP (NN:[1108..1112] MYCN) (JJ:[1113..1125] nonamplified))
            (NN:[1126..1130] cell) (NNS:[1131..1136] lines)))
        (PRN (-LRB-:[1137..1138] -LRB-)
          (S
            (NP-SBJ (NN:[1138..1139] P))
            (VP (SYM:[1140..1141] =)
              (NP (CD:[1142..1146] 0.04))))
          (-RRB-:[1146..1147] -RRB-))))
    (.:[1147..1148] .)))

;sentence 8 Span:1149..1311
;D-L(R:S) BSO (500 microM for 72 h)  induced apoptosis as detected by DNA
;laddering, nuclear morphology, and TUNEL  staining of DNA fragments using
;flow cytometry.
(SENT
  (S
    (NP-SBJ (NN:[1149..1157] D-L-LRB-R:S-RRB-) (NN:[1158..1161] BSO)
      (PRN (-LRB-:[1162..1163] -LRB-)
        (NP
          (NP (CD:[1163..1166] 500) (NN:[1167..1173] microM))
          (PP (IN:[1174..1177] for)
            (NP (CD:[1178..1180] 72) (NN:[1181..1182] h))))
        (-RRB-:[1182..1183] -RRB-)))
    (VP (VBD:[1185..1192] induced)
      (NP (NN:[1193..1202] apoptosis))
      (SBAR-ADV (IN:[1203..1205] as)
        (S
          (NP-SBJ (-NONE-:[1205..1205] *))
          (VP (VBN:[1206..1214] detected)
            (PP-MNR (IN:[1215..1217] by)
              (NP
                (NP (NN:[1218..1221] DNA) (NN:[1222..1231] laddering))
                (,:[1231..1232] ,)
                (NP (JJ:[1233..1240] nuclear) (NN:[1241..1251] morphology))
                (,:[1251..1252] ,) (CC:[1253..1256] and)
                (NP
                  (NP (NN:[1257..1262] TUNEL) (NN:[1264..1272] staining))
                  (PP (IN:[1273..1275] of)
                    (NP (NN:[1276..1279] DNA) (NNS:[1280..1289] fragments))))))
            (S-MNR
              (NP-SBJ (-NONE-:[1289..1289] *))
              (VP (VBG:[1290..1295] using)
                (NP (NN:[1296..1300] flow) (NN:[1301..1310] cytometry))))))))
    (.:[1310..1311] .)))

;sentence 9 Span:1312..1403
;Maximal cell killing occurred  within 48 h and was antagonized byic value in
;neuroblastoma.
;[1389..1402]:malignancy-type:"neuroblastoma"
(SENT
  (S
    (NP-SBJ-1 (JJ:[1312..1319] Maximal) (NN:[1320..1324] cell)
              (NN:[1325..1332] killing))
    (VP
      (VP (VBD:[1333..1341] occurred)
        (PP (IN:[1343..1349] within)
          (NP (CD:[1350..1352] 48) (NN:[1353..1354] h))))
      (CC:[1355..1358] and)
      (VP (VBD:[1359..1362] was)
        (VP (VBN:[1363..1374] antagonized)
          (NP-1 (-NONE-:[1374..1374] *))
          (PP (IN:[1375..1377] by)
            (NP-LGS (NN:[1377..1379] ic) (NN:[1380..1385] value)))
          (PP (IN:[1386..1388] in)
            (NP (NN:[1389..1402] neuroblastoma))))))
    (.:[1402..1403] .)))

;section 10 Span:1404..1435
;Copyright 1999  Academic Press.
(SEC
  (FRAG (NN:[1404..1413] Copyright) (CD:[1414..1418] 1999)
        (NNP:[1420..1428] Academic) (NNP:[1429..1434] Press) (.:[1434..1435] .)))

;section 11 Span:1439..1483
;PMID: 9882527 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[1439..1443] PMID) (::[1443..1444] :) (CD:[1445..1452] 9882527)
        (NN:[1453..1454] -LSB-) (NNP:[1454..1460] PubMed) (::[1461..1462] -)
        (NN:[1463..1470] indexed) (IN:[1471..1474] for)
        (NNP:[1475..1483] MEDLINE-RSB-)))
